KR102316721B1 - Pharmaceutical packaging sheets containing graphene - Google Patents

Abstract

The present application relates to a sheet for drug packaging comprising graphene and a method for manufacturing the sheet for drug packaging.

Description

Sheet for pharmaceutical packaging containing graphene {PHARMACEUTICAL PACKAGING SHEETS CONTAINING GRAPHENE}

The present application relates to a sheet for drug packaging comprising graphene and a method for manufacturing the sheet for drug packaging.

Polypropylene (hereinafter 'PP') is not stretched, that is, its unstretched film is called a non-stretched polypropylene film (casting polypropylene film; CPP film). The non-stretched polypropylene film is mainly used as a food packaging material or a pharmaceutical packaging material because it has excellent transparency and surface gloss, and excellent thermal bonding strength and dimensional stability.

Food packaging materials or pharmaceutical packaging materials require adequate strength to withstand external impact, and appropriate barrier properties are required for factors that affect chemical or microbial changes, such as moisture, temperature, oxygen, or light. A polypropylene film or a non-stretched polypropylene film alone does not satisfy all of the required physical properties, so a packaging material containing an aluminum foil or an aluminum deposition layer is mainly used to reinforce it. However, the packaging material containing aluminum currently on the market has a problem in that the aluminum layer is too thick, so that the entire packaging material is thick, and the amount of aluminum used is large.

Korean Patent Registration Publication No. 10-1832106

The present application, including a substrate layer, an adhesive layer, an aluminum layer and a numerical layer, which may further include graphene in each layer except for the aluminum layer, it is intended to provide a sheet for pharmaceutical packaging and a method for manufacturing the sheet for pharmaceutical packaging.

However, the problem to be solved by the present application is not limited to the above-mentioned problems, and other problems not mentioned will be clearly understood by those skilled in the art from the following description.

A first aspect of the present application, a substrate layer; a first adhesive layer formed on the base layer; an aluminum layer formed on the first adhesive layer; a second adhesive layer formed on the aluminum layer; and a resin layer formed on the second adhesive layer, as a pharmaceutical packaging sheet, wherein at least one of the base layer, the first adhesive layer, the second adhesive layer, and the resin layer comprises graphene It provides a sheet for pharmaceutical packaging.

The second aspect of the present application is to form a base layer, an aluminum layer and a resin layer, respectively, and to laminate the base layer, the aluminum layer, and the resin layer in this order, manufacturing a sheet for pharmaceutical packaging according to the first aspect A method comprising a first adhesive layer between the base layer and the aluminum layer, and a second adhesive layer between the aluminum layer and the resin layer, the base layer, the first adhesive layer, and the second adhesive layer And it provides a method for manufacturing a sheet for pharmaceutical packaging, wherein one or more layers of the resin layer include graphene.

The sheet for drug packaging comprising an aluminum layer according to embodiments of the present application, even if the thickness of the aluminum layer is thin by at least one layer of the base layer, the first adhesive layer, the second adhesive layer, and the resin layer includes graphene It can be used as pharmaceutical packaging material. Specifically, when the sheet for drug packaging is used in a drug packaging material, the increase in mechanical strength with increased flame resistance and impact resistance; increased barrier properties against moisture, oxygen, etc.; And there is an effect of increasing chemical resistance, there is an advantage that can reduce the amount of aluminum used. In addition, even when only one layer of the base layer, the first adhesive layer, the second adhesive layer, and the resin layer contains graphene, the desired effect can be exhibited, and the two layers or all layers Even including graphene, the desired effect can be exhibited.

1 is a schematic diagram showing a sheet for packaging a drug according to an embodiment of the present application.
2 is a photograph confirming the durability effect of the pharmaceutical packaging material and the conventional pharmaceutical packaging material containing graphene in one embodiment of the present application.
3 is a graph measuring the molding burst depth of the pharmaceutical packaging material according to the content of graphene, in one embodiment of the present application.

Hereinafter, embodiments and examples of the present invention will be described in detail with reference to the accompanying drawings so that those of ordinary skill in the art to which the present invention pertains can easily carry out. However, the present application may be embodied in several different forms and is not limited to the embodiments and examples described herein. And in order to clearly explain the present invention in the drawings, parts irrelevant to the description are omitted, and similar reference numerals are attached to similar parts throughout the specification.

Throughout this specification, when a part is said to be "connected" with another part, it includes not only the case where it is "directly connected" but also the case where it is "electrically connected" with another element interposed therebetween. do.

Throughout this specification, when a member is said to be “on” another member, this includes not only a case in which a member is in contact with another member but also a case in which another member is present between the two members.

Throughout this specification, when a part "includes" a certain component, it means that other components may be further included, rather than excluding other components, unless otherwise stated.

As used herein, the terms "about," "substantially," and the like are used in a sense at or close to the numerical value when the manufacturing and material tolerances inherent in the stated meaning are presented, and to aid in the understanding of the present application. It is used to prevent an unconscionable infringer from using the mentioned disclosure in an unreasonable manner.

As used throughout this specification, the term “step of doing” or “step of” does not mean “step for”.

Throughout this specification, the term "combination(s)" included in the expression of the Markush form means one or more mixtures or combinations selected from the group consisting of the components described in the expression of the Markush form, It means to include one or more selected from the group consisting of the above components.

Throughout this specification, reference to “A and/or B” means “A or B, or A and B”.

Throughout the present specification, the term "graphene" means that a plurality of carbon atoms are covalently linked to each other to form a polycyclic aromatic molecule, and the covalently linked carbon atoms are a basic repeating unit. It forms a 6-membered ring, but it is also possible to further include a 5-membered ring and/or a 7-membered ring. Accordingly, the sheet formed by the graphene may be viewed as a single layer of carbon atoms covalently bonded to each other, but is not limited thereto. The sheet formed by the graphene may have various structures, and such a structure may vary depending on the content of 5-membered rings and/or 7-membered rings that may be included in graphene. In addition, when the sheet formed of the graphene is made of a single layer, they may be laminated to each other to form a plurality of layers, and side end portions of the graphene sheet may be saturated with hydrogen atoms, but the present invention is not limited thereto.

Throughout this specification, the term "graphene oxide" is also referred to as graphene oxide, and may be abbreviated as "GO". The single-layer graphene may include a structure in which a functional group containing oxygen, such as a carboxyl group, a hydroxyl group, or an epoxy group, is bonded, but is not limited thereto.

Throughout this specification, the term "reduced graphene oxide" or "reduced graphene oxide" refers to graphene oxide with reduced oxygen ratio through a reduction process, and may be abbreviated as "rGO" However, the present invention is not limited thereto.

Throughout this specification, the term "graphene nano platelet" refers to a material having 10 to 100 carbon layers prepared by physical or chemical methods using natural graphite as "GNP". It may be abbreviated, but is not limited thereto.

Hereinafter, embodiments and examples of the present application will be described in detail with reference to the accompanying drawings. However, the present application is not limited to these embodiments and examples and drawings.

A first aspect of the present application, a substrate layer; a first adhesive layer formed on the base layer; an aluminum layer formed on the first adhesive layer; a second adhesive layer formed on the aluminum layer; and a resin layer formed on the second adhesive layer, as a pharmaceutical packaging sheet, wherein at least one of the base layer, the first adhesive layer, the second adhesive layer, and the resin layer comprises graphene It provides a sheet for pharmaceutical packaging.

Specifically, the pharmaceutical packaging sheet according to an embodiment of the present application, the thickness of the aluminum layer by at least one layer of the base layer, the first adhesive layer, the second adhesive layer, and the resin layer includes graphene. Even if it is thin, it can be used as a pharmaceutical packaging material. More specifically, when the sheet for drug packaging is used in a drug packaging material, the increase in mechanical strength with increased flame resistance and impact resistance; increased barrier properties against moisture, oxygen, etc.; And there is an effect of increasing chemical resistance, there is an advantage that can reduce the amount of aluminum used.

In one embodiment of the present application, the thickness of the aluminum layer may be about 5 μm to about 60 μm. Specifically, the thickness of the aluminum layer is about 5 μm to about 60 μm, about 12 μm to about 60 μm, about 12 μm to about 55 μm, about 12 μm to about 50 μm, about 12 μm to about 45 μm, about 12 μm to about 40 μm, about 12 μm to about 35 μm, about 12 μm to about 30 μm, about 15 μm to about 60 μm, about 20 μm to about 60 μm, about 25 μm to about 60 μm, about 30 μm to about 60 μm, about 20 μm to about 50 μm, about 25 μm to about 50 μm, about 30 μm to about 50 μm, about 35 μm to about 45 μm, or about 40 μm to about 45 μm, but is not limited thereto. it doesn't happen The sheet for pharmaceutical packaging of the prior art had durability that could be implemented as a pharmaceutical packaging material when the thickness of the aluminum layer was at least 50 μm, but the sheet for pharmaceutical packaging according to an embodiment of the present application has a thickness of the aluminum layer of less than 50 μm, the maximum Even if it is set to 5 μm, it has the effect of having durability that can be realized as a pharmaceutical packaging material.

In one embodiment of the present application, the thickness of the base layer may be about 30 μm to about 100 μm. Specifically, the thickness of the base layer is about 30 μm to about 100 μm, about 40 μm to about 100 μm, about 40 μm to about 90 μm, about 40 μm to about 80 μm, about 40 μm to about 70 μm, about 40 μm to about 60 μm, about 50 μm to about 100 μm, about 60 μm to about 100 μm, about 70 μm to about 100 μm, about 80 μm to about 100 μm, about 50 μm to about 90 μm, about 50 μm to about 80 μm or from about 60 μm to about 80 μm, but is not limited thereto.

In one embodiment of the present application, the thickness of the first adhesive layer or the second adhesive layer may be about 1 μm to about 10 μm. Specifically, the first adhesive layer or the second adhesive layer is about 1 μm to about 10 μm, about 1 μm to about 8 μm, about 1 μm to about 6 μm, about 1 μm to about 4 μm, about 3 μm to about 10 μm, about 5 μm to about 10 μm, about 7 μm to about 10 μm, about 3 μm to about 7 μm, about 4 μm to about 6 μm, or about 1 μm to about 3 μm, but is not limited thereto it doesn't happen

In one embodiment of the present application, the thickness of the resin layer may be about 10 μm to about 30 μm. Specifically, the thickness of the resin layer is about 10 μm to about 30 μm, about 15 μm to about 30 μm, about 20 μm to about 30 μm, about 25 μm to about 30 μm, about 15 μm to about 25 μm, about 15 μm to about 20 μm or about 20 μm to about 25 μm, but is not limited thereto.

Referring to Figure 1, the pharmaceutical packaging sheet according to an embodiment of the present application, the base layer 10 having a thickness of about 40 μm to about 100 μm, the aluminum layer 20 having a thickness of about 12 μm to about 60 μm, It may be composed of the first adhesive layer 401 or the second adhesive layer 402 having a thickness of about 1 μm to about 10 μm, and the resin layer 30 having a thickness of about 15 μm to about 30 μm. While the prior art has a problem of cracking or bursting even when constituting an aluminum layer of 40 μm, in one embodiment of the present application, the aluminum layer has a thickness of at least 12 μm There is an advantage that can implement a drug packaging material without a problem . In addition, as an embodiment, when a CPP film is used as the base layer, the thickness of the base layer may be 40 μm to 100 μm, and when a PVC film is used as the base layer, the thickness of the base layer is 60 μm to 100 μm. can be

1 shows a substrate layer 10; aluminum layer 20; resin layer 30; And it was composed of an adhesive layer 40 comprising a first adhesive layer 401 and a second adhesive layer 402, but this is only an example and further including a film that can be used in pharmaceutical packaging, or including less It is included in one embodiment of the present application without departing from the scope of the technical spirit of the present application. As an example, it may be composed of 5 layers, 7 layers, 9 layers, or 11 layers, including additionally a film that can be used in pharmaceutical packaging, and may consist of 2 layers including less.

In one embodiment of the present application, the graphene may increase the durability of the entire sheet for drug packaging.

In one embodiment of the present application, each of the first adhesive layer, the second adhesive layer, or both include the graphene, and the content of the graphene is the first adhesive layer and the second adhesive layer, respectively It may be 0.005 parts by weight to 10 parts by weight based on 100 parts by weight. When the content of the graphene is less than 0.005 parts by weight, the effect of increasing the durability of the drug packaging sheet is insignificant, indicating the durability of the prior art, and when the content of the graphene exceeds 10 parts by weight, the durability is lowered and the adhesive strength of the adhesive layer is lowered there is a problem. Specifically, the content of the graphene is 0.005 parts by weight to 10 parts by weight, 0.005 parts by weight to 5 parts by weight, 0.005 parts by weight to 3 parts by weight, based on 100 parts by weight of each of the first adhesive layer and the second adhesive layer, It may be 0.005 parts by weight to 2 parts by weight, 0.01 parts by weight to 2 parts by weight, 0.01 parts by weight to 1.5 parts by weight, 0.05 parts by weight to 1.5 parts by weight, or 0.1 parts by weight to 1.5 parts by weight.

In one embodiment of the present application, the base layer may include the graphene, and the content of the graphene may be 0.005 parts by weight to 10 parts by weight based on 100 parts by weight of the base layer. When the content of the graphene is less than 0.005 parts by weight, the effect of increasing the durability of the sheet for drug packaging is insignificant, indicating the durability of the prior art level, and when the content of the graphene exceeds 10 parts by weight, the durability is rather reduced compared to the prior art. there is Specifically, the content of the graphene is 0.005 parts by weight to 10 parts by weight, 0.005 parts by weight to 5 parts by weight, 0.005 parts by weight to 3 parts by weight, 0.005 parts by weight to 2 parts by weight, 0.01 with respect to 100 parts by weight of the base layer. It may be in an amount of 2 parts by weight to 2 parts by weight, 0.01 parts by weight to 1.5 parts by weight, 0.05 parts by weight to 1.5 parts by weight, or 0.1 parts by weight to 1.5 parts by weight.

In one embodiment of the present application, the resin layer may include the graphene, and the content of the graphene may be 0.005 parts by weight to 10 parts by weight based on 100 parts by weight of the resin layer. When the content of the graphene is less than 0.005 parts by weight, the effect of increasing the durability of the sheet for drug packaging is insignificant, indicating the durability of the prior art level, and when the content of the graphene exceeds 10 parts by weight, the durability is rather reduced compared to the prior art. there is Specifically, the content of the graphene is 0.005 parts by weight to 10 parts by weight, 0.005 parts by weight to 5 parts by weight, 0.005 parts by weight to 3 parts by weight, 0.005 parts by weight to 2 parts by weight, 0.01 with respect to 100 parts by weight of the resin layer. It may be in an amount of 2 parts by weight to 2 parts by weight, 0.01 parts by weight to 1.5 parts by weight, 0.05 parts by weight to 1.5 parts by weight, or 0.1 parts by weight to 1.5 parts by weight.

In one embodiment of the present application, the graphene may be selected from the group consisting of graphene, graphene oxide (GO), reduced graphene oxide (rGO), graphene nanoplatelets, and combinations thereof. have. Specifically, the graphene oxide includes a plurality of graphene oxide sheets, the reduced graphene oxide includes a plurality of reduced graphene oxide sheets, the plurality of graphene sheets and the plurality of reduced graphene sheets Each of the fin oxide sheets may include an oxygen-containing functional group and/or a pinhole. For example, the reduced graphene oxide may be prepared by peroxidizing graphite to obtain graphene oxide, and reducing the obtained graphene oxide to obtain reduced graphene oxide, but limited thereto it doesn't happen In the process of peroxidation of the graphite, oxygen-containing functional groups are generated at the edges of graphene and inside the graphene, and defects are generated and pinholes are generated, so that each of the reduced graphene oxide sheets finally obtained is an oxygen-containing functional group and/or may include a pinhole.

In one embodiment of the present application, the oxygen-containing functional group is selected from the group consisting of a hydroxyl group, an epoxy group, a carboxyl group, a ketone group, and combinations thereof. It may include, but is not limited to.

In one embodiment of the present application, the spacing of the voids between the plurality of graphene oxide sheets and the plurality of reduced graphene oxide sheets may be about 1 nm to about 20 nm, but is not limited thereto. can

In one embodiment of the present application, the size of the pinhole formed in the graphene oxide sheet and the reduced graphene oxide sheet may be about 0.1 nm to about 10 nm, but may not be limited thereto.

In one embodiment of the present application, the base layer may include polyvinyl chloride (PVC), polypropylene (PP) or non-stretched polypropylene (casting polypropylene, CPP). Specifically, the base layer is a part that becomes the surface of the pharmaceutical packaging material, and in order to implement a transparent film with high mechanical strength, polyvinyl chloride (PVC), polypropylene (PP) or non-stretched polypropylene (casting polypropylene, CPP) can be used In particular, polyvinyl chloride has excellent flexibility, excellent adhesion, tensile strength, elongation, tear strength, etc. similar to cellophane, but has less gas permeability, so it is suitable for use as a pharmaceutical packaging ingredient. In addition, the polypropylene is colorless, odorless, non-toxic and hygienic, has the advantage of being inexpensive as it has the lowest specific gravity among plastics, and has good gas permeability, so it is suitable for use as a component for pharmaceutical packaging.

In one embodiment of the present application, the aluminum layer may include an aluminum foil, but is not limited thereto.

In one embodiment of the present application, the adhesive layer may include, but is not limited to, a polyurethane-based adhesive, an acrylic adhesive, an epoxy-based adhesive, a polyolefin-based adhesive, an elastomer-based adhesive, or a fluorine-based adhesive.

In one embodiment of the present application, the resin layer may include nylon (NY), polyethylene terephthalate (PET), polypropylene (PP), or polyamide (PA). Specifically, the resin layer may use a resin that can improve shock absorption during external impact of the drug packaging material, nylon (NY), polyethylene terephthalate (PET), polypropylene (PP) or polyamide (PA) Can be used. Nylon 6, 11, 12, 66, and 610emd are commercially available, but nylon 6 is suitable as a non-stretched film. It has the advantage of low permeability.

In one embodiment of the present application, the forming tear depth of the sheet for drug packaging may be greater than 8.6 mm and less than 9.5 mm. Specifically, the drug packaging material may have increased durability by including graphene in at least one of the base layer, the first adhesive layer, the second adhesive layer, and the resin layer. Therefore, after molding the sheet for drug packaging, when a press is applied, it can have durability that does not burst even if the depth to which the sheet for drug packaging endures is deep. More specifically, the mold burst depth is greater than 8.6 mm and less than 9.5 mm; greater than 8.6 mm and less than 9.5 mm; greater than 9.0 mm and less than 9.5 mm; or greater than 9.1 mm and less than 9.5 mm.

The second aspect of the present application is to form a base layer, an aluminum layer and a resin layer, respectively, and to laminate the base layer, the aluminum layer, and the resin layer in this order, manufacturing a sheet for pharmaceutical packaging according to the first aspect A method comprising a first adhesive layer between the base layer and the aluminum layer, and a second adhesive layer between the aluminum layer and the resin layer, the base layer, the first adhesive layer, and the second adhesive layer And it provides a method for manufacturing a sheet for pharmaceutical packaging, wherein one or more layers of the resin layer include graphene.

In the first aspect and the second aspect, content that may be common to each other may be applied to both the first aspect and the second aspect even if the description thereof is omitted.

In one embodiment of the present application, forming the base layer, the resin layer or both, melt the raw material of each of the base layer and the resin layer at a temperature of 230°C to 250°C, and 700 kg of the melt It may include extruding at an extrusion rate of /h to 1000 kg/h and supplying it to a T-die, and processing the melt supplied to the T-die without drawing. At this time, when describing each average thickness, the base layer may be formed to be about 40 μm to about 100 μm, and the resin layer may be formed to be about 10 μm to about 30 μm, but is not limited thereto.

In one embodiment of the present application, the thickness of the aluminum layer may be about 5 μm to about 60 μm. Specifically, the thickness of the aluminum layer is about 5 μm to about 60 μm, about 12 μm to about 60 μm, about 12 μm to about 55 μm, about 12 μm to about 50 μm, about 12 μm to about 45 μm, about 12 μm to about 40 μm, about 12 μm to about 35 μm, about 12 μm to about 30 μm, about 15 μm to about 60 μm, about 20 μm to about 60 μm, about 25 μm to about 60 μm, about 30 μm to about 60 μm, about 20 μm to about 50 μm, about 25 μm to about 50 μm, about 30 μm to about 50 μm, about 35 μm to about 45 μm, or about 40 μm to about 45 μm, but is not limited thereto. it doesn't happen

In one embodiment of the present application, forming the aluminum layer may include processing aluminum in the form of a plate by passing a raw material (strip) containing aluminum between two rolls rotating at a recrystallization temperature or lower. . At this time, it is possible to proceed with repeated operations 1 to 35 times depending on the desired thickness. In addition, the method may include forming the aluminum layer to have an average thickness of 12 μm to 60 μm.

In one embodiment of the present application, the laminate may include, but is not limited to, dry lamination. Specifically, the first adhesive layer is to be formed through dry lamination to increase the viscosity by applying the first adhesive to at least one of the base layer and the aluminum layer, and volatilizing the diluent solvent in the same space as the drying chamber. can In addition, the second adhesive layer may be formed through dry lamination to increase the viscosity by applying the second adhesive to at least one of the aluminum layer and the resin layer, and volatilizing the diluent solvent in the same space as the drying chamber. have.

Hereinafter, the present application will be described in more detail with reference to Examples, but the present application is not limited thereto.

[Example]

1. Examples

1-1. Formation of base layer and resin layer

Polyvinyl chloride and nylon resin were prepared, melted at 240° C., and extruded at an extrusion rate of 800 kg/h, and supplied to a T-die. Thereafter, the polyvinyl chloride melt was undrawn and processed to form a base layer with an average thickness of 40 μm to 50 μm, and the nylon resin melt was undrawn and processed to form a base layer with an average thickness of 15 μm to 30 μm.

1-2. aluminum layer formation

An aluminum raw material (strip) was prepared and passed between two rolls rotating below the recrystallization temperature to process aluminum into a plate shape to form an aluminum layer having an average thickness of 35 μm to 40 μm.

1-3. Pharmaceutical packaging material formation

Laminated drug having an average thickness of 90 μm to 185 μm by placing the substrate layer, the aluminum layer, and the resin layer on the roller for lamination in order and moving the roller to take it out in the order of the substrate layer, the aluminum layer, and the resin layer A packaging material was formed. As the adhesive used for the laminate, an acrylic adhesive was used, but one containing 0.01 parts by weight of graphene based on 100 parts by weight of the total adhesive was used.

2. Comparative Example 1

A pharmaceutical packaging material was synthesized under the same conditions as in the above example, except that the thickness of the aluminum layer was implemented as 50 μm, and graphene was not included in the adhesive component.

3. Comparative Example 2

A pharmaceutical packaging material was synthesized under the same conditions as in the above example, except that the thickness of the aluminum layer was implemented as 40 μm, and graphene was not contained in the adhesive component.

Experimental Example 1: Comparison of durability of pharmaceutical packaging materials containing graphene and prior art

As a result of confirming the rupture properties of the pharmaceutical packaging materials of Examples, Comparative Examples 1 and 2 prepared above, Comparative Example 1 in which the thickness of the aluminum layer is 50 μm and the Example in which the thickness of the aluminum layer is 35 μm to 40 μm does not burst and was maintained in an intact state ( FIGS. 2A and 2C ). However, it was confirmed that Comparative Example 2 in which the thickness of the aluminum layer was 40 μm was cracked or burst on the surface ( FIG. 2 b ). Therefore, it was confirmed that Example 1 containing graphene has an effect of increased durability that can fully implement a pharmaceutical packaging material even if the aluminum layer is thinly configured, and has the advantage of significantly reducing the amount of aluminum used (Fig. 2).

Experimental Example 2: Comparison of durability through measurement of the molding burst depth of the pharmaceutical packaging material containing graphene and the prior art

A pharmaceutical packaging material was prepared in the same manner as in the above example, but a difference in effect according to the content of graphene was confirmed. Specifically, in the adhesive layer, 0.0005 parts by weight, 0.001 parts by weight, 0.005 parts by weight, 0.01 parts by weight, 0.05 parts by weight, 0.1 parts by weight, 1.0 parts by weight, 1.5 parts by weight, 2.0 parts by weight based on 100 parts by weight of the total adhesive , 2.5 parts by weight, 3.0 parts by weight, 3.5 parts by weight, 4.0 parts by weight, 4.5 parts by weight, 5.0 parts by weight of graphene was added to prepare a pharmaceutical packaging material. And the effect according to the graphene content was confirmed by measuring the molding burst depth at which the drug packaging material starts to burst. The mold tear depth refers to the depth at which the sheet withstands without rupture when a press is applied. The depth of the forming burst was judged by comparison based on the prior art already on the market, and the forming tear depth of the commercially available sheet was 8.6 mm. The results are shown in Table 1 below.

[Table 1]

As a result of confirming the molding bursting result, when the content of the graphene was 0.0005 parts by weight and 0.001 parts by weight, the molding burst depth of the pharmaceutical packaging material was 8.6 mm, confirming that it is the same as the breaking depth of the prior art. It was confirmed that the equivalent performance was shown. In addition, when the content of the graphene was 3.5 parts by weight to 5 parts by weight, the molding rupture depth of the pharmaceutical packaging material was 8.5 mm or less, and it was confirmed that the performance was lower than the standard of the existing product at 3.5 parts by weight or more. On the other hand, when the content of the graphene was 0.005 to 3.0 parts by weight, a molding rupture depth exceeding 8.6 mm appeared, and a depth of 9.4 mm (1 part by weight) was measured at the maximum, and according to the addition of graphene, the existing product It was confirmed that the effect of improving the durability was excellent compared to that of .

In addition, in Experimental Examples 1 and 2, only the case in which graphene was contained in the adhesive was confirmed, but these results confirmed that the same effect was exhibited even when the graphene was contained in the base layer or the resin layer.

The above description of the present application is for illustration, and those of ordinary skill in the art to which the present application pertains will understand that it can be easily modified into other specific forms without changing the technical spirit or essential features of the present application. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. For example, each component described as a single type may be implemented in a distributed manner, and likewise components described as distributed may also be implemented in a combined form.

The scope of the present application is indicated by the following claims rather than the above detailed description, and all changes or modifications derived from the meaning and scope of the claims, and their equivalents should be construed as being included in the scope of the present application. .

10: base layer
20: aluminum layer
30: resin layer
40: adhesive layer
401: first adhesive layer
402: second adhesive layer

Claims (12)

base layer;
a first adhesive layer formed on the base layer;
an aluminum layer formed on the first adhesive layer;
a second adhesive layer formed on the aluminum layer; and
A resin layer formed on the second adhesive layer
As a sheet for pharmaceutical packaging comprising a,
At least one of the base layer, the first adhesive layer, the second adhesive layer, and the resin layer includes graphene,
The graphene increases the durability of the entire sheet for drug packaging,
The content of the graphene will be 0.1 parts by weight to 1.5 parts by weight based on 100 parts by weight of each layer excluding the aluminum layer,
Sheets for pharmaceutical packaging.
The method of claim 1,
The thickness of the aluminum layer is 5 μm to 60 μm, the sheet for pharmaceutical packaging.
delete The method of claim 1,
Each of the first adhesive layer, the second adhesive layer, or all of them contains the graphene,
The content of the graphene will be 0.1 parts by weight to 1.5 parts by weight based on 100 parts by weight of each of the first adhesive layer and the second adhesive layer, a sheet for pharmaceutical packaging.
The method of claim 1,
The base layer includes the graphene,
The content of the graphene will be 0.1 parts by weight to 1.5 parts by weight based on 100 parts by weight of the base layer, the sheet for pharmaceutical packaging.
The method of claim 1,
The resin layer includes the graphene,
The content of the graphene is 0.1 parts by weight to 1.5 parts by weight based on 100 parts by weight of the resin layer, the sheet for pharmaceutical packaging.
The method of claim 1,
The graphene is selected from the group consisting of graphene, graphene oxide (GO), reduced graphene oxide (rGO), graphene nanoplatelets, and combinations thereof, a sheet for pharmaceutical packaging.
The method of claim 1,
The base layer will include a polyvinyl chloride (PVC), polypropylene (PP) or non-stretched polypropylene (casting polypropylene, CPP), pharmaceutical packaging sheet.
The method of claim 1,
The adhesive layer is a polyurethane-based adhesive, an acrylic adhesive, an epoxy-based adhesive, a polyolefin-based adhesive, an elastomeric adhesive or a fluorine-based adhesive, the pharmaceutical packaging sheet.
The method of claim 1,
Wherein the resin layer comprises nylon (NY), polyethylene terephthalate (PET), polypropylene (PP) or polyamide (PA), a sheet for pharmaceutical packaging.
Forming a base layer, an aluminum layer, and a resin layer, respectively,
Laminating in order of the base layer, the aluminum layer, and the resin layer
As a method for manufacturing a sheet for pharmaceutical packaging according to claim 1, comprising:
A first adhesive layer between the base layer and the aluminum layer, and a second adhesive layer between the aluminum layer and the resin layer,
At least one of the base layer, the first adhesive layer, the second adhesive layer, and the resin layer comprises graphene,
A method for manufacturing a sheet for pharmaceutical packaging.
12. The method of claim 11,
The thickness of the aluminum layer is 5 μm to 60 μm, the method for manufacturing a sheet for pharmaceutical packaging.

Images